Shots:

• Aronora to receive $6M upfront & $3M upon fulfillment of certain conditions. Xoma to get rights to royalties and 10% of milestone payments associated with five hematology assets from Aronora. The transaction is expected to close within the next 90 days
• The focus of the transaction is to expand XOMA’s portfolio with the addition of hematological & anti-thrombotic mAbs
• The five hematological assets include three anti-thrombotic candidates BAY1213790 (P-II) BAY1831865- AB023 (P-II) developed in collaboration with Bayer targeting factor XI/XIa and two other assets AB002 (P-I- thrombin analog) & AB054 (factor XII mAb) for acute cardiovascular events

Ref: Xoma | Image: NIH SBIR